Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
High Grade Upper Tract Urothelial Carcinoma
Primary: Complete Pathologic Response Rate — 0.103; 0.167 proportion of participants
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Phase 2 N=63 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 3 N=1,004 A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Urinary Tract Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 2 N=15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg
Phase 2 N=45 Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
Bladder Cancer
Primary: Progression Free Survival — 8.2 months
Phase 2 N=36 Gemzar, Cisp, Sunitinib Urothelial Ca
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Phase 3 N=71 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
Carcinoma, Transitional Cell · Transitional Cell Carcinoma of Renal Pelvis
Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants
Phase 2 N=22 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Phase 2 N=51 Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Myeloproliferative Disorder · Urothelial Carcinoma · Cancer
Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months
Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Phase 2 N=60 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Bladder Cancer
Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants
Phase 1 N=18 MK-3475/BCG in High Risk Superficial Bladder Cancer
Bladder Cancer
Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants
Phase 2 N=17 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Phase 2 N=66 Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
Primary: Overall Response Rate (ORR) — 48.5 Percentage of patients with response
Phase 3 N=175 Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
Carcinoma, Transitional Cell
Primary: Objective Response Rate (ORR) - Central Assessment — 19.5; 21.6; 19.4; 23.8 percentage of participants — p==0.6991
Phase 2 N=13 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Urothelial Carcinoma · Ureteral Neoplasms · Ureter Cancer
Primary: Progression Free Survival — 1.9 Months
Phase 3 N=506 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma
Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707
Phase 2 N=77 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants
Phase 2 N=43 CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Bladder Cancer
Primary: Objective Response Rate (ORR) — 1; 2 Participants
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 2 N=68 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Transitional Cell Carcinoma of Bladder · Urethra Cancer · Ureter Cancer
Primary: Maximum Tolerated Dose (MTD) and/or the Recommended Dose (RD) for Dose Expansion of ALT-801 in Combination With Cisplatin and Gemcitabine or ALT-801 in Combination With…
Phase 2 N=78 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Phase 2 N=22 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Phase 2 N=13 A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer
Urinary Tract Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 92.3 percentage of participants
Phase 2 N=76 Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Bladder Cancer
Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants